More than 1,400 participants across 65+ countries underscores accelerating adoption of model-informed workflows and growing demand for applied modeling expertise Simulations Plus, Inc. (Nasdaq: SLP) ( ...
Simulations Plus SLP announced the launch of GastroPlus X (GPX), which is its latest platform for physiologically based pharmacokinetics and biopharmaceutics (PBPK/PBBM) modeling and simulation. The ...
Combines validated scientific engines with accelerated computing and AI to enable more scalable, integrated modeling workflows across the drug development lifecycle Simulations Plus, Inc. (Nasdaq: SLP ...
Simulations Plus, Inc. SLP shares are trading lower on Wednesday as the company announced a collaboration with NVIDIA Corp NVDA, aimed at enhancing GPU-accelerated simulation and AI-assisted workflows ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and ...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc.
ASDs are among the most powerful yet complex oral drug delivery systems, with performance influenced by factors such as food intake, gastric pH, formulation composition, and manufacturing processes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results